132 related articles for article (PubMed ID: 21862637)
1. Therapeutic oligonucleotides: the road not taken.
Stein CA; Goel S
Clin Cancer Res; 2011 Oct; 17(20):6369-72. PubMed ID: 21862637
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.
Hong DS; Kurzrock R; Oh Y; Wheler J; Naing A; Brail L; Callies S; André V; Kadam SK; Nasir A; Holzer TR; Meric-Bernstam F; Fishman M; Simon G
Clin Cancer Res; 2011 Oct; 17(20):6582-91. PubMed ID: 21831956
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides for therapeutic intervention.
Eck SL; Nabel GJ
Curr Opin Biotechnol; 1991 Dec; 2(6):897-904. PubMed ID: 1367966
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
5. Cancer therapy finds a solid target.
Secko D
CMAJ; 2005 Aug; 173(3):246. PubMed ID: 16076816
[No Abstract] [Full Text] [Related]
6. Therapeutic Antisense Oligonucleotides Are Coming of Age.
Bennett CF
Annu Rev Med; 2019 Jan; 70():307-321. PubMed ID: 30691367
[TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
10. Antisense therapeutics: from theory to clinical practice.
Pirollo KF; Rait A; Sleer LS; Chang EH
Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotides: a new therapeutic approach.
Temsamani J; Guinot P
Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
[TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide therapeutics for human leukaemia.
Gewirtz AM
Ciba Found Symp; 1997; 209():169-91; discussion 191-4. PubMed ID: 9383576
[TBL] [Abstract][Full Text] [Related]
13. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats.
Baba M; Iishi H; Tatsuta M
Int J Cancer; 2000 Jan; 85(2):260-6. PubMed ID: 10629087
[TBL] [Abstract][Full Text] [Related]
14. [Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V
Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
[TBL] [Abstract][Full Text] [Related]
15. A status update of modified oligonucleotides for chemotherapeutics applications.
Sanghvi YS
Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
17. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.
Hong D; Kurzrock R; Kim Y; Woessner R; Younes A; Nemunaitis J; Fowler N; Zhou T; Schmidt J; Jo M; Lee SJ; Yamashita M; Hughes SG; Fayad L; Piha-Paul S; Nadella MV; Mohseni M; Lawson D; Reimer C; Blakey DC; Xiao X; Hsu J; Revenko A; Monia BP; MacLeod AR
Sci Transl Med; 2015 Nov; 7(314):314ra185. PubMed ID: 26582900
[TBL] [Abstract][Full Text] [Related]
18. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides as innovative therapeutic strategy in the treatment of high-grade gliomas.
Caruso G; Caffo M; Raudino G; Alafaci C; Salpietro FM; Tomasello F
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):53-69. PubMed ID: 19832690
[TBL] [Abstract][Full Text] [Related]
20. Antisense therapeutics.
Persidis A
Nat Biotechnol; 1999 Apr; 17(4):403-4. PubMed ID: 10207893
[No Abstract] [Full Text] [Related]
[Next] [New Search]
